Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

507 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study.
Schneider L, Ktorza N, Fourati S, Assoumou L, Courbon E, Caby F, Blanc C, Tindel M, Agher R, Marcelin AG, Calvez V, Peytavin G, Katlama C. Schneider L, et al. Among authors: blanc c. HIV Clin Trials. 2012 Sep-Oct;13(5):284-8. doi: 10.1310/hct1305-284. HIV Clin Trials. 2012. PMID: 23134629 Clinical Trial.
Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study.
Seang S, Fourati S, Keita Y, Blanc C, Tubiana R, Schneider L, Valantin MA, Caby F, Calin R, Lambert-Niclot S, Marcelin AG, Calvez V, Costagliola D, Katlama C. Seang S, et al. Among authors: blanc c. J Antimicrob Chemother. 2014 Dec;69(12):3356-9. doi: 10.1093/jac/dku265. Epub 2014 Jul 22. J Antimicrob Chemother. 2014. PMID: 25056835
Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia.
Katlama C, Soulié C, Caby F, Denis A, Blanc C, Schneider L, Valantin MA, Tubiana R, Kirstetter M, Valdenassi E, Nguyen T, Peytavin G, Calvez V, Marcelin AG. Katlama C, et al. Among authors: blanc c. J Antimicrob Chemother. 2016 Sep;71(9):2646-50. doi: 10.1093/jac/dkw186. Epub 2016 Jun 10. J Antimicrob Chemother. 2016. PMID: 27287235
Long-term follow-up of HIV-infected patients on dolutegravir monotherapy.
Tebano G, Soulié C, Schneider L, Blanc C, Agher R, Seang S, Valantin MA, Palich R, Tubiana R, Peytavin G, Marcelin AG, Assoumou L, Katlama C. Tebano G, et al. Among authors: blanc c. J Antimicrob Chemother. 2020 Mar 1;75(3):675-680. doi: 10.1093/jac/dkz478. J Antimicrob Chemother. 2020. PMID: 31800056
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
Palich R, Allavena C, Peytavin G, Soulie C, Tubiana R, Weiss L, Montoya Ferrer A, Duvivier C, Bouchaud O, Bottero J, Durand A, Lê MP, Marcelin AG, Dudoit Y, Assoumou L, Katlama C; ETRAL QD study group. Palich R, et al. J Antimicrob Chemother. 2021 Jan 19;76(2):477-481. doi: 10.1093/jac/dkaa423. J Antimicrob Chemother. 2021. PMID: 33099638 Clinical Trial.
Prevalence and factors associated with symptom persistence: A prospective study of 429 mild COVID-19 outpatients.
Faycal A, Ndoadoumgue AL, Sellem B, Blanc C, Dudoit Y, Schneider L, Tubiana R, Valantin MA, Seang S, Palich R, Bleibtreu A, Monsel G, Godefroy N, Itani O, Paccoud O, Pourcher V, Caumes E, Ktorza N, Chermak A, Abdi B, Assoumou L, Katlama C; COVIDOM-19 PSL research group. Faycal A, et al. Among authors: blanc c. Infect Dis Now. 2022 Mar;52(2):75-81. doi: 10.1016/j.idnow.2021.11.003. Epub 2021 Nov 17. Infect Dis Now. 2022. PMID: 34800742 Free PMC article.
No increased risk of Kaposi sarcoma relapse in patients with controlled HIV-1 infection after switching protease inhibitor-based antiretroviral therapy.
Lajaunie R, Cuzin L, Palich R, Makinson A, Bani-Sadr F, Duvivier C, Arvieux C, Rey D, Poizot-Martin I, Delpierre C, Delobel P, Martin-Blondel G; And The Dat’AIDS study group. Lajaunie R, et al. HIV Med. 2022 Mar;23(3):301-306. doi: 10.1111/hiv.13168. Epub 2021 Oct 19. HIV Med. 2022. PMID: 34668293 Free article.
507 results